Ideas to action: independent research for global prosperity
Research
Innovative, independent, peer-reviewed. Explore the latest economic research and policy proposals from CGD’s global development experts.
WORKING PAPERS
April 11, 2024
POLICY PAPERS
April 15, 2024
CGD NOTES
April 08, 2024
WORKING PAPERS
April 04, 2024
All Research
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
Research
POLICY PAPERS
November 03, 2022
Pull financing is a powerful but underused mechanism for incentivising progress on hard-to-tackle social problems for which innovation or the take-up of innovation may be part of the solution. It should become part of the ongoing landscape for climate and development work. This paper sets out the sp...
CGD NOTES
June 09, 2022
As one of the only truly global institutions, the World Bank is uniquely positioned to be the world’s premier source funding for global public goods. But despite its global coverage, the World Bank has never truly been oriented towards global challenges. Its mission has been defined primarily by ind...
CGD NOTES
May 24, 2022
The first section of this note examines the causes and consequences of Afghanistan’s financial crisis and lays out policy options the international community can support to enable urgent financial flows and restore the basic functioning of the Afghan financial system. The next section examines prosp...
WORKING PAPERS
May 20, 2022
Many public organizations employ technologies of scrutiny such as peer review or quality assurance to improve their performance and decision-making. Such technologies may affect performance and decision-making directly, through scrutiny, and indirectly, through behavioural responses by agents within...
BRIEFS
April 28, 2022
COVID-19 has disrupted health systems across the globe. Nigeria reported its first COVID-19 case in February 2020, and, since then, the government has rolled out four vaccines to help control the pandemic—Moderna, Oxford-Astra Zeneca (AZ), Johnson & Johnson (J&J) and Pfizer-BioNTech.